Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 16 June 2026 at 16.00 EEST

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly and indirectly by BlackRock, Inc. and its funds, and the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds decreased on 15 June 2026 below five (5) per cent of Orion Corporation’s total shares.

Total positions of BlackRock, Inc. and its funds subject to notification:

% of shares and voting rights (total of point A)

% of shares and voting rights through financial instruments (total of point B)

Total of both in % (points A + B)

Total number of shares and voting rights of issuer

Resulting situation on the date on which threshold was crossed or reached

Below 5% shares Below 5% voting rights

Below 5% shares Below 5% voting rights

Below 5% shares Below 5% voting rights

141,134,278 shares 738,091,288 voting rights

Position of previous notification (if applicable)

4.92% shares Below 5% voting rights

0.10% shares Below 5% voting rights

5.03% shares Below 5% voting rights

Notified details of the resulting situation on the date on which the threshold was crossed:

Point A: Shares and voting rights:

Class/type of shares ISIN code

Number of shares and voting rights

% of shares and voting rights

Direct (SMA 9:5)

Indirect (SMA 9:6 and 9:7)

Direct (SMA 9:5)

Indirect (SMA 9:6 and 9:7)

FI0009014377

Below 5% shares Below 5% voting rights

Below 5% shares Below 5% voting rights

POINT A SUBTOTAL

Below 5% shares Below 5% voting rights

Below 5% shares Below 5% voting rights

Point B: Financial instruments according to SMA 9:6a:

Type of financial instrument

Expiration date

Exercise / Conversion Period

Physical or cash settlement

Number of shares and voting rights

% of shares and voting rights

American Depositary Receipt (US68628Y1047)

N/A

N/A

Physical

Below 5% shares Below 5% voting rights

Below 5% shares Below 5% voting rights

Securities Lent

N/A

N/A

Physical

Below 5% shares Below 5% voting rights

Below 5% shares Below 5% voting rights

CFD

N/A

N/A

Cash

Below 5% shares Below 5% voting rights

Below 5% shares Below 5% voting rights

POINT B SUBTOTAL

Below 5% shares Below 5% voting rights

Below 5% shares Below 5% voting rights

Orion Corporation

Liisa Hurme President and CEO

Mikko Kemppainen General Counsel

Contact person: Tuukka Hirvonen, Investor Relations, Orion Corporation tel. +358 10 426 2721

Publisher:

Orion Corporation Communications Orionintie 1A, FI-02200 Espoo, Finland www.orionpharma.com

Orion Pharma is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals as well as active pharmaceutical ingredients, combining our trusted expertise with continuous innovation. We have an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by us are used to treat cancer, respiratory diseases and neurological diseases, among others. In 2025 our net sales amounted to EUR 1,890 million, and we employ about 4,000 professionals worldwide, dedicated to building well-being.